Besides the impact on fat mass, the therapeutic blockage of hepatic S6K1 also ameliorated steatosis and dyslipidemia through the molecular changes implemented in liver, as depicted by transcriptomics and lipid signatures. This evidence concerns the gene RPS6KB1 and metabolic syndrome.